RESUMO
PURPOSE: This multicenter pilot study assessed the feasibility and efficacy of a time-intensified bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) regimen given in 14-day intervals (BEACOPP-14) with granulocyte colony-stimulating factor (G-CSF) support in advanced Hodgkin's lymphoma. PATIENTS AND METHODS: From July 1997 until March 2000, 94 patients with Hodgkin's lymphoma stage IIB, III, and IV were scheduled to receive eight cycles of BEACOPP-14. Consolidation radiotherapy was administered to regions with initial bulky disease or residual tumor after chemotherapy. RESULTS: All patients were assessable for toxicity and treatment outcome. Eighty-six patients received the planned eight cycles of BEACOPP-14. Consolidation radiotherapy was given in 66 patients. Chemotherapy could generally be administered on schedule. Dose reductions varied among drugs but were generally low. Acute toxicity was moderate, with World Health Organization grade 3/4 leukopenia in 75%, thrombocytopenia in 23%, anemia in 65%, and infection in 12% of patients. A total of 88 patients (94%) achieved a complete remission. Four patients had progressive disease. At a median observation time of 34 months, five patients have relapsed, one patient developed a secondary non-Hodgkin's lymphoma, and three deaths were documented. The overall survival and freedom from treatment failure rates at 34 months were 97% (95% confidence interval [CI], 93% to 100%) and 90% (95% CI, 84% to 97%), respectively. CONCLUSION: Acceleration of the BEACOPP baseline regimen by shortening cycle duration with G-CSF support is feasible and effective with moderate acute toxicity. On the basis of these results, the German Hodgkin's Lymphoma Study Group will compare the BEACOPP-14 regimen with BEACOPP-21 escalated in a prospective multicenter randomized trial.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Doença de Hodgkin/tratamento farmacológico , Adolescente , Adulto , Anemia/induzido quimicamente , Anemia/prevenção & controle , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Bleomicina/administração & dosagem , Ciclofosfamida/administração & dosagem , Progressão da Doença , Doxorrubicina/administração & dosagem , Esquema de Medicação , Etoposídeo/administração & dosagem , Feminino , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Doença de Hodgkin/patologia , Doença de Hodgkin/radioterapia , Humanos , Leucopenia/induzido quimicamente , Leucopenia/prevenção & controle , Masculino , Pessoa de Meia-Idade , Prednisona/administração & dosagem , Procarbazina/administração & dosagem , Sobrevida , Trombocitopenia/induzido quimicamente , Trombocitopenia/prevenção & controle , Resultado do Tratamento , Vincristina/administração & dosagemRESUMO
The object of the study was to evaluate the effectiveness of ifosfamide/etoposide and mesna therapy in advanced breast cancer. A total of 44 patients with breast cancer were included in the trial. Eligibility criteria included measurable, refractory disease; prior anthracycline therapy (or its contraindication); a life expectancy of at least 3 months; and adequate hepatic, renal, CNS and bone marrow function. All patients were less than or equal to 70 years of age and had a Karnofsky performance status of greater than or equal to 50%. There were 36 evaluable cases. Sites of metastatic disease included bone (19), skin (18), liver (9), lung (14), lymph node (19), and miscellaneous (7). Treatment consisted of 1,500 mg/m2 ifosfamide given i.v. on days 1-5, 120 mg/m2 etoposide given i.v. on days 1-3, and 400 mg i.v. mesna given with and at 4 and 8 h after ifosfamide. Cycles were repeated every 28 days. Initial doses were reduced by 25% or 50% in patients who had previously undergone both chemotherapy and radiotherapy. A median of 4 cycles (range, 2-8) were given. The myelotoxicity was marked: WHO grades 3/4 leukopenia (n = 37), grades 3/4 thrombocytopenia (n = 12), and grades 2/3 anemia (n = 13). Due to myelotoxicity, dose reduction or prolongation of treatment-free intervals was necessary in 28 cases. Alopecia was seen in 35 patients and CNS toxicity, in 8. Partial remission (PR) was obtained in five cases and complete remission (CR), in three. Sites of response included the lung (5), skin (4), lymph node (5), and peritoneum (1). The duration of response was 4 (n = 2) and 8 (n = 1) months for CR and 2 (n = 2), 6 (n = 2), and 10 (n = 1) months for PR. We conclude that the ifosfamide/etoposide and mesna regimen is effective, but its myelotoxicity is treatment-limiting.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Etoposídeo/administração & dosagem , Feminino , Humanos , Ifosfamida/administração & dosagem , Mesna/administração & dosagem , Pessoa de Meia-IdadeRESUMO
Primary cultures of epidermal cells from newborn mouse skin have been established. These cultures proliferate and express typical epidermal functions for limited time in vitro. The cultured cells keratinize and exhibit strong reactivity with an epidermis specific membrane antiserum. These cells can be transformed with DMBA either in standard cultures or more easily in cultures using 3T3 feeder cells. Transformed cells have increased proliferation rate. They do not pile up or form multilayered cultures like normal counterparts. They also keratinize less. When transformed cells were grown in the air on collagen gels they formed irregular clumps with central (horn-pearl) keratinization whereas normal controls formed stratified structures. Transofmred cells exhibited reduced reactivity with tissue specific membrane antiserum. There was masking or rearrangement of tissue specific membrane antigens with simultaneous exposition of new fetal-like antigens. Their reactivity with histocompatibility antisera was only slightly reduced. Transformed cells had both numerical and structural chromosome aberrations. They grew in soft agar and they induced tumors upon transplantation in the convenient host. When transplanted as cultures (on collagen) or as suspensions into the host, transformed cells were able to form epithelial cell cords invading the underlying mesenchyme with histological aspect typical of carcinoma. Cell cultures derived from in vivo DMBA induced tumors behaved like in vitro transformed cells.
Assuntos
Transformação Celular Neoplásica/induzido quimicamente , 9,10-Dimetil-1,2-benzantraceno , Animais , Carcinoma/induzido quimicamente , Carcinoma/patologia , Transformação Celular Neoplásica/patologia , Células Cultivadas , Técnicas In Vitro , Camundongos , Transplante de Neoplasias , Neoplasias Experimentais/induzido quimicamente , Neoplasias Cutâneas/induzido quimicamente , Neoplasias Cutâneas/patologia , Transplante HomólogoAssuntos
Antígenos/análise , Hemadsorção , Pele/imunologia , Absorção , Animais , Membrana Celular/imunologia , Células Cultivadas , Eritrócitos/imunologia , Fibroblastos/imunologia , Liofilização , Adjuvante de Freund/administração & dosagem , Injeções Intradérmicas , Injeções Intramusculares , Injeções Intraperitoneais , Linfonodos/imunologia , Macrófagos/imunologia , Camundongos , Camundongos Endogâmicos C3H , Camundongos Endogâmicos , Coelhos/imunologia , Ovinos/imunologia , Baço/imunologia , Timo/imunologiaAssuntos
Células Cultivadas/citologia , Pele/citologia , Animais , Antígenos , Autorradiografia , Contagem de Células , Divisão Celular , Membrana Celular/imunologia , Sobrevivência Celular , Técnicas Citológicas , Feminino , Camundongos , Mitose , Coelhos/imunologia , Pele/imunologia , Pele/metabolismo , Solubilidade , Timidina/metabolismo , Trítio , TripsinaAssuntos
Células Epiteliais , Epitélio/imunologia , Fibroblastos/imunologia , Antígenos de Histocompatibilidade/análise , Soros Imunes , Isoanticorpos/análise , Pele/imunologia , Animais , Formação de Anticorpos , Contagem de Células , Diferenciação Celular , Técnicas de Cultura , Embrião de Mamíferos , Imunofluorescência , Linfonodos/imunologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Transplante de PeleRESUMO
BACKGROUND: The optimal treatment of elderly patients with Hodgkin's lymphoma (HL) is still a matter of debate. Since many of these patients receive combined modality treatment, we evaluated the impact of different radiation field sizes, that is extended-field (EF) or involved-field (IF) technique when given after four cycles of chemotherapy. PATIENTS AND METHODS: In the multicenter HD8 study of the German Hodgkin Study Group, 1204 patients with early-stage unfavorable HL were randomized to receive four cycles of chemotherapy followed by either radiotherapy (RT) of 30 Gy EF + 10 Gy to bulky disease (arm A) or 30 Gy IF + 10 Gy to bulky disease (arm B). A total of 1064 patients were assessable for the analysis. Of these, 89 patients (8.4%) were 60 years or older. RESULTS: Elderly patients had a poorer risk profile. Acute toxicity from RT was more pronounced in elderly patients receiving EF-RT compared with IF-RT [World Health Organization (WHO) grade 3/4: 26.5% versus 8.6%)]. Freedom from treatment failure (FFTF, 64% versus 87%) and overall survival (OS, 70% versus 94%) after 5 years was lower in elderly patients compared with younger patients. Importantly, elderly patients had poorer outcome when treated with EF-RT compared with IF-RT in terms of FFTF (58% versus 70%; P = 0.034) and OS (59% versus 81%; P = 0.008). CONCLUSION: Elderly patients with early-stage unfavorable HL generally have a poorer risk profile and outcome when compared with younger patients. Treatment with EF-RT instead of IF-RT after chemotherapy has a negative impact on survival of elderly patients and should be avoided.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Doença de Hodgkin/tratamento farmacológico , Doença de Hodgkin/radioterapia , Lesões por Radiação/etiologia , Adolescente , Adulto , Idoso , Bleomicina/uso terapêutico , Terapia Combinada , Ciclofosfamida/uso terapêutico , Dacarbazina/uso terapêutico , Progressão da Doença , Doxorrubicina/uso terapêutico , Feminino , Alemanha , Doença de Hodgkin/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prednisona/uso terapêutico , Procarbazina/uso terapêutico , Prognóstico , Taxa de Sobrevida , Resultado do Tratamento , Vimblastina/uso terapêutico , Vincristina/uso terapêuticoRESUMO
In contrast to younger patients, the prognosis of elderly patients with advanced Hodgkin's disease (HD) has not improved substantially over the last 20 years. We thus carried out a prospectively randomized study (HD9(elderly)) to compare the BEACOPP regimen in this setting against standard COPP-ABVD. Between February 1993 and 1998, 75 patients aged 66-75 years with newly diagnosed HD in advanced stages were recruited into the HD9 trial as a separate stratum (HD9(elderly)). Patients were assigned to eight alternating cycles of COPP and ABVD or eight cycles of BEACOPP in baseline doses. Radiotherapy was given to initial bulky or residual disease. In total, 68 of 75 registered patients were assessable: 26 were treated with COPP-ABVD and 42 with BEACOPP baseline. There were no significant differences between COPP-ABVD and BEACOPP in terms of complete remission (76%), overall survival (50%) and freedom from treatment failure (FFTF) (46%) at 5 years. At a median follow-up of 80 months, a total of 37 patients died: 14/26 patients (54%) treated with COPP-ABVD and 23/42 patients (55%) with BEACOPP. Two patients (8%) treated with COPP-ABVD and nine patients (21%) treated with BEACOPP died of acute toxicity. Hodgkin-specific FFTF at 5 years was 55% after COPP-ABVD and 74% after BEACOPP (P=0.13). Thus, there are no differences in survival between these regimens in elderly patients.
Assuntos
Envelhecimento , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Doença de Hodgkin/tratamento farmacológico , Administração Oral , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Bleomicina/administração & dosagem , Ciclofosfamida/administração & dosagem , Dacarbazina/administração & dosagem , Doxorrubicina/administração & dosagem , Etoposídeo/administração & dosagem , Feminino , Doença de Hodgkin/patologia , Humanos , Infusões Intravenosas , Prednisona/administração & dosagem , Procarbazina/administração & dosagem , Estudos Prospectivos , Análise de Sobrevida , Resultado do Tratamento , Vimblastina/administração & dosagem , Vincristina/administração & dosagemRESUMO
Skin autografting or a single painting with the cocarcinogen TPA was used to induce epidermal hyperplasia in the back skin of C3H mice. Initiation by intragastric application of the carcinogen DMBA during this state of hyperplasia and subsequent promotion by repeated application of the cocarcinogen TPA led to decreased papilloma-formation, as compared to mice of a control group which had not been pretreated before initiation. Reports by others referring to increased susceptibility of replicating epidermal cells to the effect of initiation thus cannot be confirmed. The reduction of papilloma-formation can most probably be ascribed to effects of local inflammation, either preferentially but unspecifically damaging initiated cells, or facilitating a specific immune response against tumor-associated transplantation antigens of prospective tumor cells.
Assuntos
Papiloma/induzido quimicamente , Transplante de Pele , 9,10-Dimetil-1,2-benzantraceno , Animais , Feminino , Hiperplasia , Camundongos , Camundongos Endogâmicos C3H , Pele/patologia , Acetato de Tetradecanoilforbol , Fatores de Tempo , Transplante AutólogoRESUMO
Combination chemotherapy with etoposide and ifosfamide in 2 patients with advanced bronchial carcinomas caused hepatotoxic side effects. Hepatotoxicity was observed during and immediately after the 5-day therapy and was characterised by a massive rise in direct bilirubin, drop in cholinesterase, as well as a rise in the alkaline phosphatase and to a lesser extent in gGT and GOT. Hepatotoxicity was lethal in one case and reversed to normal in the other. Hepatotoxicity was most likely caused by ifosfamide, since this drug was applied for the first time in both cases. Nonetheless, a contribution of etoposide in this regard can not be excluded since there were liver enzyme alterations in one case after a previous course of chemotherapy using etoposide and cis-platinum.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carcinoma de Células Pequenas/tratamento farmacológico , Carcinoma de Células Escamosas/tratamento farmacológico , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Neoplasias Pulmonares/tratamento farmacológico , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Etoposídeo/administração & dosagem , Etoposídeo/efeitos adversos , Feminino , Humanos , Ifosfamida/administração & dosagem , Ifosfamida/efeitos adversos , Testes de Função Hepática , Masculino , Pessoa de Meia-IdadeRESUMO
Two cases in adults with recurrent staphylococcal infections associated with abnormal granulocytic chemotaxis and hyperimmunoglobulinaemia E (Job's syndrome) are described. The pathophysiological mechanisms seems to consist of an abnormal IgE reaction against staphylococcal antigens causing secondary abnormality of granulocyte function. Abnormal cellular immune function was demonstrated in vitro and in vivo. Corticosteroid administration at first proved effective in both patients. One patient developed Hodgkin's disease of the mixed type in the course of the disease.
Assuntos
Hipergamaglobulinemia/complicações , Imunoglobulina E , Síndrome de Job/imunologia , Disfunção de Fagócito Bactericida/imunologia , Infecções Estafilocócicas/complicações , Corticosteroides/uso terapêutico , Adulto , Quimiotaxia , Feminino , Granulócitos/imunologia , Doença de Hodgkin/etiologia , Humanos , Síndrome de Job/tratamento farmacológico , MasculinoRESUMO
The development of epidermis and epidermal appendages from dissociated cells of neonate mouse skin was examined by transplantation of cell suspensions to subdermally prepared, protected graft beds. Using Ficol gradients and culture procedures, we prepared subfractions of primary cell suspensions consisting of essentially pure epidermal cells or fibroblasts. Reformation of an epithelium structurally similar to the epidermis was observed from transplanted epidermal-cell suspensions, but formation of hair follicles and development of normal epidermal microarchitecture was observed only when epidermal cells were transplanted together with cells of dermal origin. This pattern was observed following transplantation of either fresh-cell isolates or cells cultured up to 7 days prior to transplantation.
Assuntos
Células Epidérmicas , Pele/citologia , Animais , Diferenciação Celular , Separação Celular , Células Cultivadas , Colágeno , Células do Tecido Conjuntivo , Epiderme/transplante , Células Epiteliais , Feminino , Masculino , Camundongos , Camundongos Endogâmicos C3H , Transplante de PeleRESUMO
An autosomal erythrocytosis, inherited as a dominant, occurred in seven members of a family. The propositus was first diagnosed as having erythrocytosis at 26 years of age. He had headaches and marked plethora. Polycythaemia vera and secondary erythrocytosis of known cause were excluded. Erythropoietin level was not elevated. Two of his three children were also found to have erythrocytosis. As in this family, the disease is characterized in middle age by hypertension, cardiovascular and thromboembolic phenomena, as well as abnormal bleeding. For over eight years the propositus has been successfully treated with repeated venous blood lettings.
Assuntos
Policitemia/genética , Adulto , Idoso , Sangria , Criança , Feminino , Genes Dominantes , Humanos , Masculino , Pessoa de Meia-Idade , Linhagem , Policitemia/diagnóstico , Policitemia/terapiaRESUMO
27 patients with advanced colorectal cancer were treated in a phase-II trial with high dose sequential methotrexate (MTX), 5-fluorouracil (5-FU), and folinic acid (FA). Following a 4 h infusion of 800 mg/m2 MTX and a 4 h interval, 1,500 mg/m2 5-FU and 200 mg/m2 FA were given as a 24 h infusion. Out of 23 evaluable patients we observed one partial remission and 9 disease stabilizations. Median survival time of all patients was 10.4 months. Overall toxicity was low. In comparison to a previous trial we did not observe better treatment results by adding high dose FA to a sequential MTX/5-FU schedule.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Colorretais/tratamento farmacológico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias Colorretais/mortalidade , Esquema de Medicação , Feminino , Fluoruracila/administração & dosagem , Humanos , Leucovorina/administração & dosagem , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/secundário , Masculino , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Indução de RemissãoRESUMO
Idarubicin is a new anthracycline derivative with therapeutic efficacy in metastatic breast cancer. In a phase II trial we treated 23 patients with advanced breast carcinoma and favourable prognostic factors. Oral dose of idarubicin was 15 mg/m2 day 1-3 repeated every 3 weeks. All patients were pretreated with hormones. Idarubicin was administered as first line chemotherapy. 20 patients were evaluable for response: 3 patients achieved partial remission, 12 patients stable disease; tumour progression occurred in 5 patients. 3 patients were not evaluable for response because only 1 treatment cycle was administered. Main toxicites were leukopenia (median WHO-grade: 2,r:0-4), nausea and vomiting (median: 1,r:0-4) and alopezia (median: 1,r:0-3). 1 patient died in septic shock: Immediately after the administration of one idarubicine cycle, she was extensively irradiated because of bone metastasis. The fatal course of the disease in this patient does not depend only on the idarubicin therapy, but also on the extensive bone infiltration and on intensive radiation therapy. Idarubicin proved to be an effective drug in metastatic breast cancer with low systemic toxicity and the advantage of oral administration. The drug is an enrichment of therapeutic armament, especially in patients with soft tissue and bone metastasis.
Assuntos
Neoplasias da Mama/tratamento farmacológico , Idarubicina/administração & dosagem , Administração Oral , Idoso , Neoplasias da Mama/mortalidade , Terapia Combinada , Avaliação de Medicamentos , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Metástase Neoplásica , Taxa de SobrevidaRESUMO
The BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen, a rearranged and accelerated version of the standard COPP/adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy, has been shown to be effective and safe in a previous pilot study for advanced stage Hodgkin's disease (HD). The present study aimed to determine a maximum practicable dose of three drugs, ie, etoposide, adriamycin, and cyclophosphamide, for which acute toxicities were acceptable and to assess the feasibility of the escalated scheme. Sixty untreated patients with advanced stage HD were enrolled in this study. Radiotherapy was given in 44 patients (73%) after chemotherapy to initial bulk lesions and residual disease. Granulocyte-colony stimulating factor (G-CSF) was given from day 8 to prevent prolonged neutrocytopenia and severe infections. The intended doses of adriamycin, etoposide, and cyclophosphamide in the BEACOPP schedule could be substantially escalated: adriamycin from 25 to 35, cyclophosphamide from 650 to 1,200, and etoposide from 100 to 200 mg/m2. The major toxicities were leukocytopenia and thrombocytopenia with considerable heterogeneity between individual patients. Of 60 patients, 56 (93%) achieved a complete remission (CR). At a median observation of 32 months, the rates of survival and freedom from treatment failure (FFTF) were estimated to be 91% (95% confidence interval 83% to 99%) and 90% (82% to 98%). These results show that a moderate dose escalation of adriamycin, cyclophosphamide, and etoposide of the baseline BEACOPP regimen is feasible. The escalated BEACOPP regimen shows very encouraging results in advanced stage HD and is now being compared in a randomized phase III study with BEACOPP at baseline dose level.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Doença de Hodgkin/tratamento farmacológico , Radioterapia Adjuvante , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Bleomicina/administração & dosagem , Bleomicina/efeitos adversos , Ciclofosfamida/administração & dosagem , Ciclofosfamida/efeitos adversos , Relação Dose-Resposta a Droga , Doxorrubicina/administração & dosagem , Doxorrubicina/efeitos adversos , Esquema de Medicação , Etoposídeo/administração & dosagem , Etoposídeo/efeitos adversos , Feminino , Filgrastim , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Doença de Hodgkin/mortalidade , Doença de Hodgkin/patologia , Doença de Hodgkin/radioterapia , Humanos , Leucemia/induzido quimicamente , Masculino , Pessoa de Meia-Idade , Segunda Neoplasia Primária/induzido quimicamente , Prednisona/administração & dosagem , Prednisona/efeitos adversos , Procarbazina/administração & dosagem , Procarbazina/efeitos adversos , Proteínas Recombinantes , Indução de Remissão , Taxa de Sobrevida , Resultado do Tratamento , Vincristina/administração & dosagem , Vincristina/efeitos adversosRESUMO
BACKGROUND: The purpose of this study was to compare the efficacy of the hybrid chemotherapeutic regimen COPP/ABV/IMEP (cyclophosphamide-vincristine-procarbazine-prednisone-doxorubicin-bleomycin-vinblastine-ifosfamide-methotrexate-etoposide) (CAI) with that of the standard regimen COPP/ABVD (COPP/ABV, dacarbacine) (CA) in the treatment of advanced-stage Hodgkin's disease (HD). PATIENTS AND METHODS: Between January 1988 and January 1993, 588 eligible patients with HD in stages IIIB and IV were randomly assigned to a treatment or control group. The treatment group received four cycles of CAI over a complete cycle duration of 43 days. The control group received four cycles of CA over 57 days. Both groups then received consolidating radiotherapy. RESULTS: Five hundred and eighty-four patients were suitable for arm comparison. Patients in each group were similar in age, sex, histological subtype and clinical risk factors. Complete remission rates, overall survival and freedom from treatment failure at 7 years were similar for the two groups: 77% versus 78%, 73% versus 73% and 54% versus 56% for CAI and CA, respectively. Differences in acute chemotherapy-related toxicity were significant, however. Prognostic factor analysis confirmed the relevance of the International Prognostic Index and revealed that stage IVB, low hemoglobin, low lymphocyte count, high age and male gender were associated with a poor prognosis CONCLUSION: The rapidly alternating hybrid CAI did not give superior results when compared with the standard regimen CA in advanced-stage HD.